Minimal Residual Disease Gains Max US FDA AdComm Support For Myeloma Trials
Executive Summary
The US FDA’s Oncologic Drugs Advisory Committee unanimously agreed that accelerated approvals should be enabled by multiple myeloma trials using MRD as a surrogate endpoint.